= 0.007). These findings suggest that HER2 may play a role in the progression of malignant HGNs, particularly HGCs. This preliminary study highlights the potential of HER2 as a diagnostic marker and emphasizes the need for further investigation into its prognostic value and role in HER2-targeted therapy for canine HGCs.
No takes yet. Share an insight, caveat, or question.
BOONSRIROJ et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: